NYSE
MYOV

Myovant Sciences Ltd

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Myovant Sciences Ltd Stock Price

Vitals

Today's Low:
$26.98
Today's High:
$27
Open Price:
$26.99
52W Low:
$16.26
52W High:
$27.06
Prev. Close:
$26.99
Volume:
2213982

Company Statistics

Market Cap.:
$2.62 billion
Book Value:
-5.752
Revenue TTM:
$379.11 million
Operating Margin TTM:
-38.75%
Gross Profit TTM:
$72.02 million
Profit Margin:
-48.47%
Return on Assets TTM:
-18.22%
Return on Equity TTM:
0%

Company Profile

Myovant Sciences Ltd had its IPO on 2016-10-27 under the ticker symbol MYOV.

The company operates in the Healthcare sector and Biotechnology industry. Myovant Sciences Ltd has a staff strength of 579 employees.

Stock update

Shares of Myovant Sciences Ltd opened at $26.99 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $26.98 - $27, and closed at $26.98.

This is a -0.04% slip from the previous day's closing price.

A total volume of 2,213,982 shares were traded at the close of the day’s session.

In the last one week, shares of Myovant Sciences Ltd have increased by +0.07%.

Myovant Sciences Ltd's Key Ratios

Myovant Sciences Ltd has a market cap of $2.62 billion, indicating a price to book ratio of 70.0114 and a price to sales ratio of 7.7963.

In the last 12-months Myovant Sciences Ltd’s revenue was $379.11 million with a gross profit of $72.02 million and an EBITDA of $-145576992. The EBITDA ratio measures Myovant Sciences Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Myovant Sciences Ltd’s operating margin was -38.75% while its return on assets stood at -18.22% with a return of equity of 0%.

In Q4, Myovant Sciences Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 84.1%.

Myovant Sciences Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-1.92 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Myovant Sciences Ltd’s profitability.

Myovant Sciences Ltd stock is trading at a EV to sales ratio of 7.796 and a EV to EBITDA ratio of -17.3357. Its price to sales ratio in the trailing 12-months stood at 7.7963.

Myovant Sciences Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$403.52 million
Total Liabilities
$245.75 million
Operating Cash Flow
$5.26 million
Capital Expenditure
$228000
Dividend Payout Ratio
0%

Myovant Sciences Ltd ended 2024 with $403.52 million in total assets and $0 in total liabilities. Its intangible assets were valued at $403.52 million while shareholder equity stood at $-558143000.00.

Myovant Sciences Ltd ended 2024 with $350.01 million in deferred long-term liabilities, $245.75 million in other current liabilities, 2000.00 in common stock, $-1376614000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $250.59 million and cash and short-term investments were $274.44 million. The company’s total short-term debt was $2,703,000 while long-term debt stood at $358.70 million.

Myovant Sciences Ltd’s total current assets stands at $386.59 million while long-term investments were $0 and short-term investments were $23.85 million. Its net receivables were $44.02 million compared to accounts payable of $12.22 million and inventory worth $30.08 million.

In 2024, Myovant Sciences Ltd's operating cash flow was $5.26 million while its capital expenditure stood at $228000.

Comparatively, Myovant Sciences Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$26.98
52-Week High
$27.06
52-Week Low
$16.26
Analyst Target Price
$27

Myovant Sciences Ltd stock is currently trading at $26.98 per share. It touched a 52-week high of $27.06 and a 52-week low of $27.06. Analysts tracking the stock have a 12-month average target price of $27.

Its 50-day moving average was $26.92 and 200-day moving average was $21.14 The short ratio stood at 11.21 indicating a short percent outstanding of 0%.

Around 4861.1% of the company’s stock are held by insiders while 5621.1% are held by institutions.

Frequently Asked Questions About Myovant Sciences Ltd

The stock symbol (also called stock or share ticker) of Myovant Sciences Ltd is MYOV

The IPO of Myovant Sciences Ltd took place on 2016-10-27

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$166.81
3.05
+1.86%
$18.18
0.3
+1.68%
$26.76
0
0%
$4.63
0.03
+0.65%
$66.38
-1.24
-1.83%
$2.17
-0.05
-2.25%
$120.1
0
0%
$13.56
0.01
+0.07%
$2.01
-0.04
-1.95%
Moderna Inc (MRNA)
$105.24
-0.56
-0.53%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women’s health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Address

11-12 St. James?s Square, London, United Kingdom, SW1Y 4LB